The exploratory study sponsored by Changzhou No.2 People's Hospital aims to evaluate the safety and efficacy of NKG2D CAR-NK cell injections for treating refractory recurrent multiple myeloma (MM). Given the increasing incidence of MM and the limitations of current therapies, including CAR-T cell therapy, this approach may address a significant unmet medical need. The market for MM therapies is expanding, with a focus on innovative cell therapies. If successful, this asset could position itself as a competitive alternative to existing treatments, particularly in patients with relapsed/refractory disease who are not candidates for traditional therapies. The trial's outcomes could influence future development strategies and partnerships in the immunotherapy landscape.